by The global Next-generation Sequencing Data Analysis market size is expected to be worth around US$ 5.72 billion by 2030, according to a new report by Vision Research Reports.
The global Next-generation Sequencing Data Analysis market size was valued at US$ 571.6 million in 2020 and is anticipated to grow at a CAGR of 16.2% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39034
Growth Factors
The easy availability of genomic and proteomic data is expected to create lucrative growth opportunities for this market during the forecast period. In addition, a decrease in the cost of sequencing is expected to increase the adoption rate of NGS, which, in turn, is likely to boost the market growth. The availability of tools such as Agilent’s HaloPlex capture system and Targeted Methyl-Seq platform from EpiGentek Group Inc. has helped in the determination of DNA methylation profiles in individual genomes.
The COVID-19 pandemic has accelerated the usage of NGS and created a massive requirement for NGS data analysis solutions. The NGS tools were able to generate a considerable amount of data for researchers to study and analyze the pathogenesis. The professionals from academia, industry and government have used sequencing and data analysis technology to assist in understanding the characteristics, processes, and phylogenetics ofSARS‐CoV‐2.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 5.72 billion by 2030 |
| Growth Rate | CAGR of 16.2% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, Workflow, Mode, Read length, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Golden Helix, Inc.; Bio-Rad Laboratories, Inc.; SciGenom Labs Pvt. Ltd.; DNAnexus Inc.; Genuity Science; Fabric Genomics, Inc.; Congenica Ltd.; QIAGEN; DNASTAR, Inc.; Pacific Biosciences of California, Inc.; Eurofins Scientific; Partek Incorporated; Precigen Bioinformatics Germany GmbH; PierianDx; Agilent Technologies, Inc.; F. Hoffmann-La Roche Ltd.; Illumina, Inc.; Verily Life Science; Thermo Fisher Scientific, Inc. |
By Product Analysis
The services segment dominated the market with a revenue share of over 50.0% in 2020. Cost-effective NGS data analysis services are readily adopted by establishments that lack the required infrastructure for data management, analysis, and interpretation.
CLC Genomics Workbench offered by QIAGEN is one such data interpretation tools toolkit for epigenomics, genomics, metagenomics, and transcriptomics in one single program. Many companies are engaged in delivering products for data processing, i.e., data analysis tools that enable research entities to carry out projects using NGS.
Illumina, Genomatix, QIAGEN, and DNAStarare some of the companies that provide software and tools for the interpretation of generated data. Illumina and QIAGEN are the largest providers of software. Other key players such as ThermoFisher Scientific also offer commercial software for the analysis of NGS data.
By Workflow Analysis
NGS tertiary data analysis dominated the market in 2020 with a revenue share of over 45.0%. Various annotation tools are utilized for NGS tertiary data analysis and companies are adopting strategic initiatives to expand the scope of these tools.
Secondary data analysis is anticipated to register the fastest CAGR over the forecast period. The rising application of whole-genome sequencing requires faster secondary analysis tools to fulfill the increasing demand.
The field-programmable gate arrays are logic circuits that represent higher efficiency and speed as compared to conventional CPUs, especially for customized genomic analysis. On the other hand, cloud service providers including Amazon Web Services possess large data centers with large capacities to process a large number of samples simultaneously.
By Mode Analysis
In-house mode accounted for the largest revenue share of over 65.0% in 2020. The in-house mode includes companies that are involved in disease testing and diagnosis using NGS while conducting their analysis using available technology and software tools. Such companies operating in this segment are rapidly increasing.
The in-house analysis also allows quick incorporation of innovative scientific workflows into bioinformatics pipelines. These factors are responsible for the largest share of this segment and the segment is likely to maintain its lead during the forecast period.
Outsourced mode is expected to register the fastest CAGR over the forecast period. Considering the cost advantages offered by outsourcing mode, companies such as SciBergprovide outsourced services.
By Read Length Analysis
Short-read sequencing dominated the market in 2020 with a share of over 75.0% owing to the wide adoption and the availability of alignment tools and algorithms for short-read sequencing data.
DRAGEN is a Bio-IT Platform that provides an ultra-rapid secondary analysis of sequencing data from whole genome, whole exome, and targeted sequencing workflows.
The market shows lucrative opportunities for long and very long read sequencing segments. Guppy offered by Oxford Nanopore is a data processing toolkit that includes bioinformatic post-processing features and basecalling algorithms.
By End-use Analysis
The academic research segment led the market in 2020 with a revenue share of over 50.0%. The growth can be attributed to a rise in the adoption of the workflows process in academic institutions.
The University of Pittsburgh has established centers to perform sequencing, bioinformatics analysis, and high-performance computing to assist researchers with their ongoing academic research and projects.
The clinical research segment is expected to expand at the fastest growth rate from 2021 to 2028. Research initiatives for the development of in vitro tests using sequencing technology are expected to influence the growth of the clinical research segment.
PierianDx offers Clinical Genomicist Workspace software that provides clinical laboratories a more accurate and streamlined analysis, along with reporting and interpretation for personalized medicine programs.
By Regional Analysis
Europe held the largest revenue share of over 45.0%in 2020. This can be attributed to the presence of a significant number of key players, such as Illumina, Thermo Fisher Scientific, and Agilent Technologies, along with the presence of several organizations operating in this region that incorporates data analysis software.
Asia Pacific is expected to register the fastest growth rate over the forecast period. There has been significant progress in understanding the molecular basis of cancer with the use of sequencing technologies in Japan.
Key Players
- Thermo Fisher Scientific, Inc.
- QIAGEN
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- PierianDx
- Precigen Bioinformatics Germany GmbH
- Partek Incorporated
- Eurofins Scientific
- Pacific Biosciences of California, Inc.
- DNASTAR, Inc.
- Congenica Ltd.
- Fabric Genomics, Inc.
- Genuity Science
- DNAnexus Inc.
- SciGenom Labs Pvt. Ltd.
- Golden Helix, Inc.
- Verily Life Science
Market Segmentation
- By Product
- Services
- NGS Commercial Software
- Platform OS/UI
- Analytical Software
- QC/Pre-processing Tools
- Alignment Tools & Software
- DNA Seq Alignment
- RNA Seq Alignment
- Protein Seq Alignment
- Others
- By Workflow
- Primary
- Secondary
- Read Mapping
- Variant Alignment & Variant Calling
- Tertiary
- Variant Annotation
- Application Specific
- Targeted Sequencing/ Gene Panel
- Exome
- RNA Seq
- Whole Genome
- Chip Seq
- Others
- By Mode
- In-house
- Outsourced
- By Read Length
- Short Read Sequencing
- Long Read Sequencing
- Very Long Read Sequencing
- By End-use
- Academic Research
- Clinical Research
- Hospitals & Clinics
- Pharma& Biotech Entities
- Other Users
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Middle East Africa (MEA)
- South Africa
- Saudi Arabia
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Next-generation Sequencing Data Analysis Market, By Product
7.1. Next-generation Sequencing Data Analysis Market, by Product, 2021-2030
7.1.1. Services
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. NGS Commercial Software
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Next-generation Sequencing Data Analysis Market, By Workflow
8.1. Next-generation Sequencing Data Analysis Market, by Workflow, 2021-2030
8.1.1. Primary
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Secondary
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Tertiary
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Next-generation Sequencing Data Analysis Market, By Mode
9.1. Next-generation Sequencing Data Analysis Market, by Mode, 2021-2030
9.1.1. In-house
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Outsourced
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Next-generation Sequencing Data Analysis Market, By Read Length
10.1. Next-generation Sequencing Data Analysis Market, by Read Length, 2021-2030
10.1.1. Short Read Sequencing
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Long Read Sequencing
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Very Long Read Sequencing
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Next-generation Sequencing Data Analysis Market, By End-use
11.1. Next-generation Sequencing Data Analysis Market, by End-use, 2021-2030
11.1.1. Academic Research
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Clinical Research
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Hospitals & Clinics
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Pharma& Biotech Entities
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Next-generation Sequencing Data Analysis Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.1.3. Market Revenue and Forecast, by Mode (2017-2030)
12.1.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.1.5. Market Revenue and Forecast, by End-use (2017-2030)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Mode (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.1.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.1.7. Rest of North America
12.1.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.7.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.1.7.3. Market Revenue and Forecast, by Mode (2017-2030)
12.1.7.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.1.7.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.3. Market Revenue and Forecast, by Mode (2017-2030)
12.2.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.2.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Mode (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.2.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2.7. Germany
12.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Mode (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.2.7.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2.8. France
12.2.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Mode (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.2.8.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2.9. Rest of Europe
12.2.9.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.9.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.9.3. Market Revenue and Forecast, by Mode (2017-2030)
12.2.9.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.2.9.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.3. Market Revenue and Forecast, by Mode (2017-2030)
12.3.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.3.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Mode (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.3.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3.7. China
12.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Mode (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.3.7.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3.8. Japan
12.3.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Mode (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.3.8.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3.9. Rest of APAC
12.3.9.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.9.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.9.3. Market Revenue and Forecast, by Mode (2017-2030)
12.3.9.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.3.9.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.3. Market Revenue and Forecast, by Mode (2017-2030)
12.4.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.4.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Mode (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.4.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4.7. North Africa
12.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Mode (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.4.7.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4.8. South Africa
12.4.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Mode (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.4.8.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4.9. Rest of MEA
12.4.9.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.9.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.9.3. Market Revenue and Forecast, by Mode (2017-2030)
12.4.9.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.4.9.5. Market Revenue and Forecast, by End-use (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.5.3. Market Revenue and Forecast, by Mode (2017-2030)
12.5.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.5.5. Market Revenue and Forecast, by End-use (2017-2030)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Mode (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.5.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.5.7. Rest of LATAM
12.5.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.7.2. Market Revenue and Forecast, by Workflow (2017-2030)
12.5.7.3. Market Revenue and Forecast, by Mode (2017-2030)
12.5.7.4. Market Revenue and Forecast, by Read Length (2017-2030)
12.5.7.5. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 13. Company Profiles
13.1. Thermo Fisher Scientific, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. QIAGEN
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Illumina, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffmann-La Roche Ltd.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Agilent Technologies, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Bio-Rad Laboratories, Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. PierianDx
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Precigen Bioinformatics Germany GmbH
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Partek Incorporated
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Eurofins Scientific
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39034
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
